SCHEMBL949278

SCHEMBL949278

CC(C)(C)OC(=O)N1CCC(NC(=O)c2cnc3ccccn23)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.54
POLB P06746 2/20 0.52
CCNA2 P20248 1/20 0.50
CDK2 P24941 1/20 0.50
LMNA P02545 1/20 0.49
THRB P10828 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.47
PARP1 P09874 1/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
EPHX1 P07099 1/20 0.46
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
HDAC4 P56524 1/20 0.46
ALDH1A1 P00352 1/20 0.46
KIT P10721 1/20 0.46
NAMPT P43490 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL949286 0.80 HPGDS (0.49) POLBLMNATHRBMAPTMEN1
SCHEMBL13199301 0.77 KDM4E (0.68) USP30POLBLMNATHRBMEN1
SCHEMBL8063381 0.76 USP30 (0.68) USP30POLBLMNATHRBL3MBTL1
SCHEMBL2796947 0.76 CKS1B (0.53) POLBLMNAMAPTALDH1A1KIT
SCHEMBL23107983 0.76 USP30 (0.64) USP30POLBLMNATHRBL3MBTL1
SCHEMBL16002920 0.74 SYK (0.49) CCNA2CDK2MEN1KMT2AEPHX1
SCHEMBL31500996 0.74 CDK2 (0.58) CDK2
SCHEMBL948655 0.74 EPHX1 (0.50) USP30POLBLMNATHRBL3MBTL1
SCHEMBL24231865 0.74 IRAK4 (0.56) USP30CDK2
SCHEMBL17181322 0.73 USP30 (0.54) USP30POLBLMNATHRBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-13 US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 US disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 USP30 3776/4885POLB 2031/4885CCNA2 500/4885
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE F2, H1-3, CYC1 USP30 3986/4885POLB 1843/4885CCNA2 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.